Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00082511 · ClinicalTrials.gov registry record · Phase 3
GL701 (Prestara™) in Women With Systemic Lupus Erythematosus Receiving Treatment With Glucocorticoids
A Phase 3 study of Systemic Lupus Erythematosus, sponsored by Genelabs Technologies.
- Completed
- Registry status
- Phase 3
- Development phase
- 114
- Enrollment target
- 20
- Study locations
NCT00082511: Completed Phase 3 study of Systemic Lupus Erythematosus, sponsored by Genelabs Technologies.
NCT00082511 is a Phase 3 study of Systemic Lupus Erythematosus that has completed, run by Genelabs Technologies. The registered enrollment target is 114 participants, below the 379-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (70% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00082511, a Phase 3 study of Systemic Lupus Erythematosus, has completed, sponsored by Genelabs Technologies.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 114 participants
- Enrollment target
- 20
- Study locations
Study Summary
Open label safety and efficacy follow-up.
Conditions Studied
Interventions
- DRUG Prasterone (GL701)
Study Locations (20)
California
- Wallace Rheumatic Study Center - Los Angeles
- Lifestyles Health Science Center - Rancho Mirage
- University of California San Diego - San Diego
- East Bay Rheumatology Group - San Leandro
Florida
- Center for Rheumatology, Immunology and Arthritis - Fort Lauderdale
- Rheumatology Associates of Central Florida - Orlando
- Tampa Medical Group, P.A. - Tampa
New York
- SUNY Downstate Medical Center - Brooklyn
- North Shore University Hospital, Division of Rheumatology - Manhasset
- Albert Einstein Medical School - The Bronx
Missouri
- St. John's Medical Research Group - Springfield
- Washington University School of Medicine - St Louis
Pennsylvania
- Altoona Center for Clinical Research - Duncansville
- University of Pittsburgh - Pittsburgh
Arizona
- University of Arizona - Tucson
Illinois
- Northwestern University - Chicago
Maryland
- Johns Hopkins University - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 114 participants |
| Start Date | 2003-07 |
| Est. Completion | 2005-08 |
| Phase | Phase 3 |
What the finished NCT00082511 record still lists
NCT00082511 is an interventional study that assigns participants to a tested intervention. The registered 114 participants enrollment target is mid-sized for trials with a published cap, below the 379-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (70% lower).
The record links to 1 condition, with Systemic Lupus Erythematosus appearing as the primary indexed condition, and to 1 intervention - of which Prasterone (GL701) is the first listed.
NCT00082511 names 20 study sites across 11 states, led by California, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT00082511 about?
NCT00082511 is a clinical study titled "GL701 (Prestara™) in Women With Systemic Lupus Erythematosus Receiving Treatment With Glucocorticoids". Open label safety and efficacy follow-up.
What is the current status of trial NCT00082511?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 114 participants. The study started on 2003-07. Estimated completion is 2005-08.
What conditions does trial NCT00082511 study?
This clinical trial studies the following conditions: Systemic Lupus Erythematosus.
What interventions are being tested in trial NCT00082511?
The interventions under investigation include: Prasterone (GL701) (DRUG).
Who is sponsoring clinical trial NCT00082511?
This trial is sponsored by Genelabs Technologies, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00082511 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Systemic Lupus Erythematosus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00082511's enrollment target sits among peer trials
114 53rd of 99 higher than 47 of 99 other Systemic Lupus Erythematosus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Systemic Lupus Erythematosus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
RECRUITING · Phase 3
-
Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease
RECRUITING · Phase 3
-
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
RECRUITING · Phase 3
-
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
RECRUITING · Phase 3
-
A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04522791 · 114 participants · Phase 2
Breathing, Relaxation, Attention Training, & Health in Older Adults (BREATHE)
- NCT04875052 · 114 participants · NA
Vibration and Post-traumatic Osteoarthritis Risk Following ACL Injury
- NCT05100342 · 114 participants
Prospective Validation of a Points Score System Predicting 30-day Survival
- NCT05224089 · 114 participants · Phase 4
Bilateral TAP and RS Blocks Using Liposomal Bupivacaine/Bupivacaine vs. Regular Bupivacaine in Laparoscopic Colectomy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia